Skip to main content

Table 3 Characteristics at Near-Adult Height

From: Presenting features and long-term effects of growth hormone treatment of children with optic nerve hypoplasia/septo-optic dysplasia

 

ONH/SOD

Non-ONH/SOD

 

N

Median

10th, 90th

percentiles

N

Median

10th, 90th

percentiles

P-value

 

At GH Start

     

Gender, males

59

26 (44.1%)

 

23

10 (43.5%)

  

Age (years)

59

5.64

2.14, 11.76

23

5.12

2.09, 12.04

0.546

Height SDS

59

-3.77

-5.51, -1.96

23

-4.97

-7.73, -2.98

< 0.001

Height - Mid-Parental Height SDS

48

-3.41

-5.85, -1.78

22

-3.30

-5.81, -0.91

0.658

Weight SDS

59

-2.23

-4.44, -0.72

23

-3.49

-5.92, -0.80

0.013

BMI SDS

59

-0.13

-2.02, 1.86

23

0.09

-1.64, 1.56

0.955

GH Dose (mg/kg/week)

59

0.21

0.14, 0.31

23

0.21

0.14, 0.43

0.996

 

At NAH

     

Age (years)

59

17.73

15.5, 20.5

23

17.30

15.3, 19.4

0.369

Height SDS

59

-0.87

-2.8, 0.6

23

-1.37

-2.7, 0.2

0.430

Δ Height SDS (Latest minus Start)

59

2.75

1.1, 4.4

23

3.37

1.6, 6.1

0.025

Height - Mid-Parental Height SDS

48

-0.63

-2.35, 0.87

22

0.37

-1.59, 1.43

0.004

Weight SDS

59

-0.53

-2.6, 2.7

23

-0.22

-2.1, 1.9

0.988

BMI SDS

59

0.32

-1.90, 2.50

23

0.59

-0.90, 2.50

0.581

Mean Total GH Dose (mg/kg/week)

59

0.19

0.13, 0.28

23

0.19

0.14, 0.25

0.722

Years on GH Treatment

59

11.15

6.69, 16.37

23

11.51

6.71, 14.69

0.996

Hypogonadism

59

23 (39.0%)

 

23

9 (39.1%)

  
  1. SDS, standard deviation score; GH, growth hormone